Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.12.2014 | short review | Ausgabe 4/2014

memo - Magazine of European Medical Oncology 4/2014

Angiogenesis inhibition, hypoxia, and targeting the bone marrow microenvironment in multiple myeloma: new strategies and targets

Zeitschrift:
memo - Magazine of European Medical Oncology > Ausgabe 4/2014
Autoren:
MD Normann Steiner, PhD Johann Kern, PhD Gerold Untergasser, Univ.-Doz. Eberhard Gunsilius

Abstract

Multiple myeloma (MM) is a hematological B-cell malignancy that has still a fatal prognosis. Although the treatments have improved, one major problem in MM is the clinical resistance to available drugs and combination therapies over time. Novel agents, such as oral proteasome inhibitors, monoclonal antibodies, second generation immunomodulatory drugs and therapies targeting the cell signaling and the tumor microenvironment are in development for the treatment of relapsed/refractory MM. In this review, we refer on the role of new strategies targeting the tumor microenvironment, especially on angiogenesis, hypoxia and other interactions between MM and bone marrow components.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 4/2014

memo - Magazine of European Medical Oncology 4/2014Zur Ausgabe

editorial

Angiogenesis